Current Report Filing (8-k)
21 Julio 2020 - 7:04AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
July 21, 2020
SIBANNAC, INC.
(Exact name of registrant as specified in
its charter)
|
Nevada
|
|
333-122009
|
|
33-0903494
|
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
|
of Incorporation)
|
|
|
|
Identification Number)
|
|
|
|
|
|
|
9535 E Doubletree Ranch
Road, Ste 120
Scottsdale, AZ 85258
Tel. (480) 407-6445
(Address and Telephone Number of Principal
Executive Offices)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section
12(b) of the Act: None
Securities registered pursuant to Section
12(g) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, $0.001 par value
|
N/A
|
N/A
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b 2 of this chapter). Emerging growth company ☐
If any emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
SIBANNAC, INC.
Form 8-K
Current Report
|
|
ITEM 1.01.
|
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
|
On July 15, 2020, the
Company entered into a Memorandum of Understanding acknowledging ongoing negotiations of a licensing agreement with C LAB PHARMA,
SA/MitoSynergy (“Licensor”), located in the British Virgin Islands. Closing drafts of the Licensing agreement have
been distributed to the parties.
The Licensor has been
awarded multiple U.S. patents for molecular compounds for bioavailable coppers, namely Cuprous Nicotinic Acid. These patented compounds
involve the only known bioavailable Copper 1 in the Copper 1 oxidative state. Licensor has raw materials on-hand and production
capabilities for large scale manufacturing. Finished products will be made in Sibannac’s facility, which has obtained FDA
registration for food grade manufacturing.
The U.S. Patents to
be licensed under the agreement are: WO2016/037181 and 20150224112. More information about
Copper 1 can be found in the following videos:
https://youtu.be/2jtSDvxunYI
https://youtu.be/N9YFkLvy6GY
The Licensor has performed
a human study on the Copper Niacin compound and submitted results to the Food and Drug Administration (“FDA”). In response,
the FDA issued a No Objection Letter: #910, allowing the Copper compound to be marketed as an Initial New Dietary Ingredient
(“IND”).
The proposed Licensing
agreement will provide for the development, marketing and sale of consumer products based on Copper 1 and CBD formulations, to
be branded as YourCopper, providing enhanced maintenance for the common immune system. The products will be formulated to address
some of the most common consumer symptoms – Energy, Pain and Focus - in the burgeoning nutraceutical market, estimated to
be in excess of U.S. $400 Billion over five years.
Forward-Looking Statements
This Current Report
on Form 8-K includes statements that may constitute “forward-looking” statements, usually containing the words “believe”,
“estimate”, “project”, “anticipate”, “expect” or similar expressions. These statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements
inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
SIBANNAC, INC.
|
|
Date: July 21, 2020
|
By: /s/ David Mersky
|
|
|
|
|
David Mersky
|
|
|
|
Chief Executive Officer
|
Sibannac (PK) (USOTC:SNNC)
Gráfica de Acción Histórica
De Ene 2025 a Feb 2025
Sibannac (PK) (USOTC:SNNC)
Gráfica de Acción Histórica
De Feb 2024 a Feb 2025
